BACKGROUND: Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results. METHODS: We performed a critical review in according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. From a total 768 published articles that matched our search terms, 5 studies with minimum follow-up of 24 months were selected for comparison and data analyzed in terms of baseline characteristics, functional, and sexual health outcomes. RESULTS: Included in the analyses are five studies with a minimum follow-up of 24 months. A total of 386 patients underwent PUL and 322 patients (83.4%) are available for follow-up at 24 months. The randomized studies are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Qmax) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups. CONCLUSION: PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.
BACKGROUND: Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results. METHODS: We performed a critical review in according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. From a total 768 published articles that matched our search terms, 5 studies with minimum follow-up of 24 months were selected for comparison and data analyzed in terms of baseline characteristics, functional, and sexual health outcomes. RESULTS: Included in the analyses are five studies with a minimum follow-up of 24 months. A total of 386 patients underwent PUL and 322 patients (83.4%) are available for follow-up at 24 months. The randomized studies are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Qmax) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups. CONCLUSION: PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.
Authors: Jennifer L St Sauver; Debra J Jacobson; Cynthia J Girman; Michael M Lieber; Michaela E McGree; Steven J Jacobsen Journal: J Urol Date: 2006-03 Impact factor: 7.450
Authors: Giuseppe Magistro; Christopher R Chapple; Mostafa Elhilali; Peter Gilling; Kevin T McVary; Claus G Roehrborn; Christian G Stief; Henry H Woo; Christian Gratzke Journal: Eur Urol Date: 2017-07-19 Impact factor: 20.096
Authors: Claus G Roehrborn; Daniel B Rukstalis; Jack Barkin; Steven N Gange; Neal D Shore; Jonathan L Giddens; Damien M Bolton; Barrett E Cowan; Anthony L Cantwell; Kevin T McVary; Alexis E Te; Shahram S Gholami; William G Moseley; Peter T Chin; William T Dowling; Sheldon J Freedman; Peter F Incze; K Scott Coffield; Fernando D Borges; Prem Rashid Journal: Can J Urol Date: 2015-06 Impact factor: 1.344
Authors: Peter T Chin; Damien M Bolton; Greg Jack; Prem Rashid; Jeffrey Thavaseelan; R James Yu; Claus G Roehrborn; Henry H Woo Journal: Urology Date: 2012-01 Impact factor: 2.649
Authors: Henry H Woo; Peter T Chin; Thomas A McNicholas; Harcharan S Gill; Mark K Plante; Reginald C Bruskewitz; Claus G Roehrborn Journal: BJU Int Date: 2011-05-06 Impact factor: 5.588
Authors: Patrick Jones; G N Rajkumar; Bhavan Prasad Rai; Omar M Aboumarzouk; Paul Cleaveland; Shalom J Srirangam; Bhaskar K Somani Journal: Urology Date: 2016-05-18 Impact factor: 2.649
Authors: Thomas A McNicholas; Henry H Woo; Peter T Chin; Damien Bolton; Manuel Fernández Arjona; Karl-Dietrich Sievert; Martin Schoenthaler; Ulrich Wetterauer; Eric J E J Vrijhof; Steven Gange; Francesco Montorsi Journal: Eur Urol Date: 2013-01-19 Impact factor: 20.096
Authors: K M C Verhamme; J P Dieleman; G S Bleumink; J L H R Bosch; B H Ch Stricker; M C J M Sturkenboom Journal: Eur Urol Date: 2003-11 Impact factor: 20.096